	US 12,263,194 B2
	Bacillus bacterium, interleukin-22 production inducing agent, skin barrier function enhancing agent
Toshihiko Kumazawa, Toyohashi (JP); Atsuhisa Nishimura, Toyohashi (JP); Noriyuki Asai, Toyohashi (JP); and Takahiro Adachi, Tokyo (JP)
Assigned to ICHIBIKI CO., LTD., Nagoya (JP); and NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, Tokyo (JP)
Filed by ICHIBIKI CO., LTD., Nagoya (JP); and NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, Tokyo (JP)
Filed on Mar. 16, 2023, as Appl. No. 18/184,711.
Application 18/184,711 is a continuation of application No. 16/970,018, abandoned, previously published as PCT/JP2019/005693, filed on Feb. 15, 2019.
Claims priority of application No. 2018-026444 (JP), filed on Feb. 16, 2018.
Prior Publication US 2023/0263841 A1, Aug. 24, 2023
Int. Cl. A61K 35/742 (2015.01); A61P 17/00 (2006.01); C12N 1/20 (2006.01); C12R 1/07 (2006.01)

CPC A61K 35/742 (2013.01) [A61P 17/00 (2018.01); C12N 1/20 (2013.01); C12N 1/205 (2021.05); C12R 2001/07 (2021.05)]

6 Claims

1. A method for inducing interleukin-22 production in a subject, comprising:

administering a Bacillus bacterium to a subject, wherein the Bacillus bacterium induces the production of interleukin-22;

wherein the Bacillus bacterium is a Bacillus bacterium of Accession number NITE BP-02583, a Bacillus bacterium of Accession number NITE BP-02584, or a Bacillus bacterium of Accession number NITE BP-02590.